Merck Raises 2023 Sales Forecast as Cancer Drug Keytruda, Gardasil Vaccine Surge
Merck & Co.’s Keytruda and Gardasil soundly beat analysts’ estimates for quarterly sales, driving the company’s annual revenue forecast higher even as costs for its acquisition of Prometheus Biosciences Inc. led to an earnings outlook cut.






